Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 105,947

Document Document Title
WO/2014/190398A1
An inhibitor of amyloid fibril formation comprising: (a) a backbone that is hydrophobic or hydrophilic and comprises from 1 to about 1000 repeating units; (b) one or more hydrophobic or hydrophilic pendant chains linked to the backbone, ...  
WO/2014/192865A1
The present invention relates to a therapeutic agent for neurodegenerative diseases and mental diseases, which comprises, as an active ingredient, a compound represented by formula (1) [wherein Z1 represents a halogen atom, an alkyl grou...  
WO/2014/191547A1
The present invention concerns a compound having the following formula (I) for its use as drug in the treatment and/or the prevention of depressions, with the proviso that said compound is not for use as drug in the treatment of women de...  
WO/2014/192868A1
The present invention provides cyclic aminomethyl pyrimidine derivatives and pharmaceutically permissible salts thereof that exhibit high selectivity for dopamine D4 receptors and are useful as therapeutic agents for attention deficit hy...  
WO/2014/191992A1
This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibito...  
WO/2014/193781A1
The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula (I), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula (I) to treat ...  
WO/2014/192698A1
A therapeutic agent for pain that is characterized by comprising 1-[3-(9H-carbazol-9-yl)propyl]-4-(2-methoxyphenyl)-4-piperid inol or a pharmaceutically acceptable salt thereof. Thus, provided is a therapeutic agent for pain that is capa...  
WO/2014/191396A1
The invention relates to a pharmaceutical dosage form comprising: (i) at least one formed segment (S1), which contains a first pharmacologically active ingredient (A1) and provides prolonged release thereof, and (ii) at least one further...  
WO/2014/190763A1
Provided are polyethylene glycol drug conjugates of general formula (I), (II) or (III) and pharmaceutical compositions and a use thereof. The conjugates are formed by combining low molecular weight polyethylene glycol with 2-4 drug molec...  
WO/2014/190758A1
Disclosed are an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis/trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for...  
WO/2014/192022A1
The present invention provides pharmaceutical compositions of rasagiline, its enantiomer or salts thereof. In particular, the invention relates to stabilizer free pharmaceutical compositions of rasagiline, its enantiomer or salts thereof...  
WO/2014/187945A1
Compositions for prevention or treatment of non-inflammatory neuronal damage from brain trauma and strokes are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of ...  
WO/2014/187654A1
The present invention is referred to novel polymeric conjugates to which at least it is linked a fibril disruptor agent and/or a aggregates blocking agent, and additionally a targeting moiety and/or a probe for therapy and diagnosis. In ...  
WO/2014/189071A1
 Provided are stem cells for transplantation composed of MSCs capable of overexpression of IL-10 as means for providing: MSCs for transplantation having improved take ratio and cell survivability after transplantation, and having high ...  
WO/2014/187225A1
Disclosed are a use of mefloquine in the preparation of a medication for preventing neuropathic pain and a pharmaceutical composition comprising a prophylactically effective amount of mefloquine and a pharmaceutical acceptable carrier.  
WO/2014/188193A1
The present invention relates to compounds of the formula (I): as inhibitors of peptidylarginine deiminases (PADs). It also concerns their use in therapy, particularly in the prophylaxis or treatment of neural injury, and other condition...  
WO/2014/187946A1
Compositions for treatment or prevention of autism disorders are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations the...  
WO/2014/190270A1
The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in ne...  
WO/2014/188980A1
The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: thi...  
WO/2014/188046A1
The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and am...  
WO/2014/187365A1
The present invention relates to a oxabicyclo derivative, preparation method and use thereof, specifically to oxabicyclo derivatives shown by general formula (I) or hydrates, solvates, stereoisomers thereof, pharmaceutically acceptable s...  
WO/2014/187922A1
Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein A and Z may be the same or different and are each independently selected from C, N, O and S; each...  
WO/2014/188329A3
This disclosure relates to a transdermal therapeutic system (TTS) containing pramipexole or related compounds and methods of making the system as well as its use in administering such compounds as a single dose over an extended period, f...  
WO/2014/190030A1
Alzheimer's disease is treated by attacking hyperactive microglia preferably before excessive beta amyloid is built up by administering tin-117m-DOTA annexin V. This compound in low radioactive doses selectively binds to the aged hyperac...  
WO/2014/190150A1
Methods for the efficient isolation and use of pluripotent adipose-derived stem cells (PASCs) are provided. In certain embodiments the methods involve providing an adipose tissue sample from which the stromal vascular fraction is co-cult...  
WO/2014/190313A3
The application relates to Dynorphin A analog compounds and uses thereof for treating pain in humans and lower animals; the compounds interact with the bradykinin receptor to relieve pain. The preferred compounds are [des-Arg7]-dynorphin...  
WO/2014/187942A1
Compositions for treatment or prevention of neurodegenerative disorders are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combi...  
WO/2014/187943A1
Compositions for treatment or prevention of depression are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Icilin and combinations thereof. Methods fo...  
WO/2014/189947A1
The present disclosure is generally directed to compositions and methods for treating apicomplexan protozoan related disease, such as toxoplasmosis and cryptosporidiosis.  
WO/2014/186824A1
Methods and implants for treating neurological, muscular and other cells having an electrical potential, with an infusion of antagonists or inverse agonists (such as flumazenil for the benzodiazepine receptor, or naltrexone for the opiat...  
WO/2014/187879A3
The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) recepto...  
WO/2014/186878A1
Provided are methods and agents for depleting senescent cells endogenous to a subject, involving administering to the subject a binding agent that is selectively toxic to senescent cells in an amount effective to reduce the number of suc...  
WO/2014/190271A2  
WO/2014/187226A1
Disclosed are use of levorotary mefloquine in the preparation of a medication for preventing or treating neuropathic pain and a pharmaceutical composition comprising a therapeutically effective amount of levorotary mefloquine and a pharm...  
WO/2014/188329A4
This disclosure relates to a transdermal therapeutic system (TTS) containing pramipexole or related compounds and methods of making the system as well as its use in administering such compounds as a single dose over an extended period, f...  
WO/2014/190139A1
The present invention relates to a use of composition comprising a glucose anti-metabolite and/or source of glucose anti-metabolite in a method of enhancing a positive affect and/or energetic arousal in a mammal.  
WO/2014/187879A2
The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) recepto...  
WO/2014/188197A1
This invention relates to the use of a very low dose of tacrolimus or a close structural analogue to treat a disease characterised by deposition of protein aggregates in neuronal cells. More particularly this invention relates to the use...  
WO/2014/184973A1
Provided is a transplantation adjuvant for neural progenitor cells, said transplantation adjuvant comprising valproic acid and/or zonisamide as active ingredient(s).  
WO/2014/184327A1
This invention relates to novel (Cyano-dimethyl-methyl)-isoxazolesand -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 recept...  
WO/2014/186310A1
The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), w...  
WO/2014/183520A1
Provided are a thiophene miazines derivate with a general formula (I), a pharmaceutical salt thereof, a preparation method therefor, and an application for being used as a therapeutical agent for treating a cancer and particularly used a...  
WO/2014/186400A1
As follows from the Background section, above, there is a need in the art for improved methods for the treatment of mood and/or anxiety disorders. The present disclosure provides therapeutic agents and methods for treating mood (e.g., Ma...  
WO/2014/184275A1
The invention relates to 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to...  
WO/2014/183220A1
The present invention relates to a method of producing expandable cultured brain cells. The brain cells are neurotrophic factor (NTF) positive. The expandable cultured brain cells are obtained by culturing a biopsy obtained from the cort...  
WO/2014/183630A1
The present invention provides a compound as represented by formula I, which has a structure as follows: R1 and R2 are glycosyl, R3 is H, hydroxyl or methoxyl; R4 is hydroxyl or methoxyl; and R5 is H, hydroxyl or methoxyl. The present in...  
WO/2014/184234A1
A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 an...  
WO/2014/185470A1
The present invention addresses the problem of providing a method for producing a graft material, which has a high restoring effect on dysfunction caused by nerve damage, at a high efficiency and a high reproducibility. Provided are a me...  
WO/2014/185481A1
Provided is a cell membrane transport promoter for the selective 5-HT1A serotonin receptors. This cell membrane transport promoter for the selective 5-HT1A serotonin receptors contains as an active ingredient 8-[2-(2-pentyl-cyclopropylme...  
WO/2014/180229A1
Disclosed is a use of bionic recombinant high density lipoprotein (HDL) in the preparation of drugs for preventing and treating Alzheimer's disease. The bionic recombinant HDL consists of lipid and apoprotein. The apoprotein is one or mo...  

Matches 551 - 600 out of 105,947